JP2024545887A5 - - Google Patents
Info
- Publication number
- JP2024545887A5 JP2024545887A5 JP2024536467A JP2024536467A JP2024545887A5 JP 2024545887 A5 JP2024545887 A5 JP 2024545887A5 JP 2024536467 A JP2024536467 A JP 2024536467A JP 2024536467 A JP2024536467 A JP 2024536467A JP 2024545887 A5 JP2024545887 A5 JP 2024545887A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- active ingredient
- adjusting agent
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210021736.1 | 2022-01-10 | ||
| CN202210021736 | 2022-01-10 | ||
| PCT/CN2023/071277 WO2023131325A1 (zh) | 2022-01-10 | 2023-01-09 | 一种稳定的受体激动剂的药物组合物、制备方法及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024545887A JP2024545887A (ja) | 2024-12-13 |
| JP2024545887A5 true JP2024545887A5 (https=) | 2026-01-22 |
Family
ID=87073306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024536467A Pending JP2024545887A (ja) | 2022-01-10 | 2023-01-09 | 安定した受容体アゴニストの医薬組成物、製造方法及びその応用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250170218A1 (https=) |
| EP (1) | EP4464331A4 (https=) |
| JP (1) | JP2024545887A (https=) |
| KR (1) | KR20240135785A (https=) |
| CN (1) | CN118488848A (https=) |
| AU (1) | AU2023205290A1 (https=) |
| CA (1) | CA3242599A1 (https=) |
| MX (1) | MX2024007861A (https=) |
| TW (1) | TW202333775A (https=) |
| WO (1) | WO2023131325A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12102664B2 (en) * | 2023-12-27 | 2024-10-01 | Olfactive Biosolutions, LLC | Compositions and methods for treating endocrine diseases and disorders |
| US12290550B1 (en) | 2023-12-27 | 2025-05-06 | Olfactive Ai, Inc. | Compositions and methods for treating endocrine diseases and disorders |
| WO2025191149A1 (en) * | 2024-03-15 | 2025-09-18 | Krka, D.D., Novo Mesto | Pharmaceutical composition comprising dual gip and glp-1 receptor agonist |
| WO2026007980A1 (zh) * | 2024-07-03 | 2026-01-08 | 上海海雁医药科技有限公司 | 一种mor受体激动剂的液体组合物及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101366692A (zh) * | 2007-08-15 | 2009-02-18 | 江苏豪森药业股份有限公司 | 一种稳定的艾塞那肽制剂 |
| AU2013205144B2 (en) * | 2008-06-17 | 2015-07-16 | Indiana University Research And Technology Corporation | GIP-based mixed agonists for treatment of metabolic disorders and obesity |
| CN102363633B (zh) * | 2011-11-16 | 2013-11-20 | 天津拓飞生物科技有限公司 | 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用 |
| TWI705820B (zh) * | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| CN112351994B (zh) * | 2019-04-11 | 2024-06-07 | 江苏豪森药业集团有限公司 | 一种多受体激动剂及其医药用途 |
| CN111825758B (zh) * | 2019-04-19 | 2024-11-22 | 上海翰森生物医药科技有限公司 | Glp-1和gip共激动剂化合物 |
| CN110684082B (zh) * | 2019-10-08 | 2021-12-10 | 江苏诺泰澳赛诺生物制药股份有限公司 | Gip和glp-1双激动多肽化合物及药学上可接受的盐与用途 |
| CN113383014B (zh) * | 2019-11-15 | 2024-06-18 | 江苏豪森药业集团有限公司 | 双受体重激动剂化合物及其药物组合物 |
| EP4110800A1 (en) * | 2020-03-06 | 2023-01-04 | Sanofi | Peptides as selective gip receptor agonists |
| CN114349828B (zh) * | 2020-11-27 | 2023-12-08 | 江苏师范大学 | Glp-1/胰高血糖素受体双重激动剂及其应用 |
-
2023
- 2023-01-09 JP JP2024536467A patent/JP2024545887A/ja active Pending
- 2023-01-09 WO PCT/CN2023/071277 patent/WO2023131325A1/zh not_active Ceased
- 2023-01-09 MX MX2024007861A patent/MX2024007861A/es unknown
- 2023-01-09 EP EP23737187.7A patent/EP4464331A4/en active Pending
- 2023-01-09 AU AU2023205290A patent/AU2023205290A1/en active Pending
- 2023-01-09 CA CA3242599A patent/CA3242599A1/en active Pending
- 2023-01-09 US US18/727,070 patent/US20250170218A1/en active Pending
- 2023-01-09 KR KR1020247026226A patent/KR20240135785A/ko active Pending
- 2023-01-09 CN CN202380016384.3A patent/CN118488848A/zh active Pending
- 2023-01-10 TW TW112101047A patent/TW202333775A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024545887A5 (https=) | ||
| JP4353544B2 (ja) | アミリン作動薬ペプチド用製剤 | |
| TW201100093A (en) | Preparation comprising insulin, nicotinamide and an amino acid | |
| JP2005537232A (ja) | アミリンアゴニストペプチドの製剤 | |
| TW202202139A (zh) | 以２－〔（４－｛６－〔（４－氰基－２－氟苄基）氧基〕吡啶－２－基｝哌啶－１－基）甲基〕－１－〔（２ｓ）－氧雜環丁烷－２－基甲基〕－１ｈ－苯並咪唑－６－甲酸或其藥學上的鹽治療第２型糖尿病或肥胖症或體重過重 | |
| JP2024545887A (ja) | 安定した受容体アゴニストの医薬組成物、製造方法及びその応用 | |
| US20210338603A1 (en) | Combinations of adrenergic receptor agonists for the treatment of type 2 diabetes | |
| AU2005271526B2 (en) | Antidiabetic oral insulin-biguanide combination | |
| KR20210087465A (ko) | 안정한 세마글루티드 조성물 및 이의 용도 | |
| JP2019530700A (ja) | ポリエチレングリコールロキセナチドを含有する薬物製剤及びその製造方法 | |
| TWI837615B (zh) | 含腸促胰島素(incretin)類似物之組合物及其用途 | |
| WO2021012947A1 (zh) | FGF21 Fc融合蛋白、GLP-1 Fc融合蛋白及它们的组合治疗剂和用途 | |
| TW202417035A (zh) | 提派肽(tirzepatide)組合物及用途 | |
| EP4591875A1 (en) | Dual glp-1 and gip receptor agonist pharmaceutical composition and use thereof | |
| US20240350590A1 (en) | Composition for orally administered formulation containing glp-1 analogue | |
| JP2024501256A (ja) | 治療用ペプチド製剤 | |
| US20140107130A1 (en) | Oral Solution Formulations of Aripiprazole | |
| EA018442B1 (ru) | Применение l-карнитина для лечения гипертензии, для снижения систолического или пульсового давления крови у субъектов с предиабетом | |
| CA3011062A1 (en) | Pharmaceutical formulations for the treatment of diabetes | |
| JP2022540862A (ja) | 高濃度インスリン製剤 | |
| JP2022523303A (ja) | グルコース代謝障害の長時間作用型の予防または治療に使用するためのβ－ラクタム化合物またはその塩 | |
| WO2019242764A1 (zh) | 糖苷类化合物在制备防治糖尿病并发症的药物中的应用 | |
| RU2803237C2 (ru) | Стабильные композиции на основе семаглутида и их варианты применения | |
| US20250114431A1 (en) | Compound, composition and methods for lowering circulating glucose | |
| US11471512B2 (en) | Pharmaceutical compositions of a peptide |